Rokit America, the U.S. subsidiary of biotechnology firm Rokit Healthcare, announced plans to accelerate its expansion across the Americas, positioning itself as a strategic hub for reverse-aging and regenerative medicine platforms, according to the company.
Rokit America reported that since its founding in 2019, it has grown into a nutraceutical business centered on a reverse-aging platform, with 2024 revenue of about USD 3.1 million and a compound annual growth rate of 71 percent between 2020 and 2024, the company said that this revenue stream provides a solid foundation for advancing more complex biotech innovations.
Going forward, the company plans to collaborate closely with its parent to integrate its reverse-aging platform with organ regeneration efforts across the region. Rokit America intends to commercialize technologies protected by U.S. patents in areas such as 3D bioprinting, cartilage regeneration, and diabetic foot ulcer regeneration, the company claims.
Rokit America aims to partner with leading U.S. research institutions and hospitals to bring its regenerative therapies to market. By leveraging both its existing infrastructure in the Americas and its intellectual property, the firm seeks to influence the direction of the emerging regenerative medicine sector.
